These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3532605)

  • 1. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials.
    Meadors GF; Gibbs PH; Peters CJ
    Vaccine; 1986 Sep; 4(3):179-84. PubMed ID: 3532605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up.
    Kark JD; Aynor Y; Peters CJ
    Am J Epidemiol; 1982 Nov; 116(5):808-20. PubMed ID: 6890766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response of steers, goats and sheep to inactivated Rift Valley Fever vaccine.
    Yedloutschnig RJ; Dardiri AH; Walker JS; Peters CJ; Eddy GA
    Proc Annu Meet U S Anim Health Assoc; 1979; (83):253-60. PubMed ID: 298921
    [No Abstract]   [Full Text] [Related]  

  • 4. Rift Valley fever vaccine--antibody and immune response in cattle to a live and an inactivated vaccine.
    Barnard BJ
    J S Afr Vet Assoc; 1979 Sep; 50(3):155-7. PubMed ID: 551199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rift Valley fever virus vaccine trial: study of side-effects in humans.
    Niklasson B
    Scand J Infect Dis; 1982; 14(2):105-9. PubMed ID: 7201671
    [No Abstract]   [Full Text] [Related]  

  • 6. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans.
    Niklasson B; Peters CJ; Bengtsson E; Norrby E
    Vaccine; 1985 Jun; 3(2):123-7. PubMed ID: 4036271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.
    Rusnak JM; Gibbs P; Boudreau E; Clizbe DP; Pittman P
    Vaccine; 2011 Apr; 29(17):3222-9. PubMed ID: 21354483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Rissmann M; Ulrich R; Schröder C; Hammerschmidt B; Hanke D; Mroz C; Groschup MH; Eiden M
    Vaccine; 2017 Jan; 35(4):655-662. PubMed ID: 28012779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine--TSI-GSD 200.
    Frank-Peterside N
    Afr J Med Med Sci; 2000 Jun; 29(2):89-92. PubMed ID: 11379456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
    Morrill JC; Mebus CA; Peters CJ
    Am J Vet Res; 1997 Oct; 58(10):1110-4. PubMed ID: 9328663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection.
    Kark JD; Aynor Y; Peters CJ
    Vaccine; 1985 Jun; 3(2):117-22. PubMed ID: 4036270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental infection and protection of lambs with a minute plaque variant of Rift Valley fever virus.
    Moussa MI; Abdel-Wahab KS; Wood OL
    Am J Trop Med Hyg; 1986 May; 35(3):660-2. PubMed ID: 3706629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.
    Morrill JC; Mebus CA; Peters CJ
    Am J Vet Res; 1997 Oct; 58(10):1104-9. PubMed ID: 9328662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of a formalin-inactivated Rift Valley fever vaccine: evaluation of a vaccination campaign for cattle in Mozambique.
    Lagerqvist N; Moiane B; Bucht G; Fafetine J; Paweska JT; Lundkvist A; Falk KI
    Vaccine; 2012 Oct; 30(46):6534-40. PubMed ID: 22947138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus.
    Morrill JC; Peters CJ
    J Infect Dis; 2011 Jul; 204(2):229-36. PubMed ID: 21673033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
    Ikegami T
    Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting.
    Bull World Health Organ; 1983; 61(2):261-8. PubMed ID: 6602663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels.
    Daouam S; Ghzal F; Naouli Y; Tadlaoui KO; Ennaji MM; Oura C; El Harrak M
    BMC Vet Res; 2016 Jul; 12(1):154. PubMed ID: 27457539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development.
    Caplen H; Peters CJ; Bishop DH
    J Gen Virol; 1985 Oct; 66 ( Pt 10)():2271-7. PubMed ID: 4045430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inactivated rift valley fever vaccine.
    Barnard BJ; Botha MJ
    J S Afr Vet Assoc; 1977 Mar; 48(1):45-8. PubMed ID: 874947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.